• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂蛋白(a)水平对心血管风险评估的影响。

Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation.

机构信息

Department of Cardiology, Hospital Italiano de Buenos Aires, Perón 4190, C1199ABB, Ciudad Autónoma de Buenos Aires, Argentina.

Argentine Group for the Study of Lp(a) [GAELp(a)], Buenos Aires, Argentina.

出版信息

High Blood Press Cardiovasc Prev. 2024 Jul;31(4):381-388. doi: 10.1007/s40292-024-00649-x. Epub 2024 May 13.

DOI:10.1007/s40292-024-00649-x
PMID:38739258
Abstract

INTRODUCTION

A new cardiovascular risk (CVR) calculator that incorporates Lipoprotein(a) [Lp(a)] levels has recently been designed.

AIMS

To estimate CVR using the new score and to identify the reduction in low-density lipoprotein cholesterol (LDL-C) or systolic blood pressure (SBP) necessary to balance the risk attributable to Lp(a).

METHODS

CVR throughout life and at 10 years was estimated with the new score in patients in primary prevention, both considering and not considering the value of Lp(a). When the estimated risk considering Lp(a) levels exceeded the baseline risk, the reduction in LDL-C levels or SBP necessary to balance the risk attributable to Lp(a) was calculated.

RESULTS

In total, 671 patients (mean age 54.2 years, 47.2% women) were included. Globally, 22.7% of the population had high Lp(a) values (> 50 mg/dL or > 125 nmol/L). When calculating CVR throughout life and considering the Lp(a) value, the global risk increased in 66.7% of cases (median 19.3%). Similar results were observed when we assessed the 10-year risk. The risk associated with Lp(a) could be completely compensated by decreasing LDL-C (average 21 mg/dL) or SBP (average 6.3 mmHg) in 79.2% and 74.7% of cases, respectively.

CONCLUSION

When calculating the CVR with the new score, two-thirds and one-third of the population were bidirectionally recategorized as 'up' or 'down,' respectively. The decrease in LDL-C or SBP mitigated the increased risk caused by Lp(a) levels across a substantial proportion of patients.

摘要

简介

最近设计了一种新的心血管风险(CVR)计算器,该计算器纳入了脂蛋白(a)[Lp(a)]水平。

目的

使用新评分估算 CVR,并确定降低低密度脂蛋白胆固醇(LDL-C)或收缩压(SBP)以平衡 Lp(a)归因风险所需的幅度。

方法

在初级预防中,考虑和不考虑 Lp(a)值,使用新评分估算终生和 10 年的 CVR。当考虑 Lp(a)水平的估计风险超过基线风险时,计算降低 LDL-C 水平或 SBP 以平衡 Lp(a)归因风险所需的幅度。

结果

共纳入 671 例患者(平均年龄 54.2 岁,47.2%为女性)。总体而言,22.7%的人群 Lp(a)值较高(>50mg/dL 或>125nmol/L)。在计算终生 CVR 并考虑 Lp(a)值时,66.7%的病例(中位数 19.3%)的总体风险增加。当评估 10 年风险时,也观察到了类似的结果。通过降低 LDL-C(平均 21mg/dL)或 SBP(平均 6.3mmHg),可以分别在 79.2%和 74.7%的病例中完全补偿与 Lp(a)相关的风险。

结论

使用新评分计算 CVR 时,三分之二和三分之一的人群分别双向重新分类为“升高”或“降低”。在相当一部分患者中,降低 LDL-C 或 SBP 减轻了 Lp(a)水平升高引起的风险增加。

相似文献

1
Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation.脂蛋白(a)水平对心血管风险评估的影响。
High Blood Press Cardiovasc Prev. 2024 Jul;31(4):381-388. doi: 10.1007/s40292-024-00649-x. Epub 2024 May 13.
2
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.PCSK9 抑制剂对脂蛋白(a)的降低作用与主要不良心血管事件:依洛尤单抗 3 期临床试验的汇总分析。
Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.
3
Is lipoprotein(a) measurement important for cardiovascular risk stratification in children and adolescents?脂蛋白(a)测量在儿童和青少年心血管风险分层中的重要性如何?
Ital J Pediatr. 2024 Sep 4;50(1):161. doi: 10.1186/s13052-024-01732-8.
4
Lipoprotein(a) and Increased Cardiovascular Risk in Women.脂蛋白(a)与女性心血管疾病风险增加
Clin Cardiol. 2016 Feb;39(2):96-102. doi: 10.1002/clc.22500. Epub 2016 Feb 16.
5
Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion.脂蛋白 (a) 与 2 型糖尿病慢性完全闭塞患者造影冠状动脉侧支循环中含胆固醇脂质的相互作用。
Cardiovasc Diabetol. 2019 Jun 24;18(1):82. doi: 10.1186/s12933-019-0888-z.
6
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.在一级预防环境中,脂蛋白(a)升高与心血管疾病风险的相关性在低低密度脂蛋白胆固醇水平时减弱。
Eur Heart J. 2018 Jul 14;39(27):2589-2596. doi: 10.1093/eurheartj/ehy334.
7
Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk.脂蛋白(a)作为心血管疾病的生物标志物及潜在的降低风险的新疗法。
Curr Vasc Pharmacol. 2024;22(3):171-179. doi: 10.2174/0115701611267835231210054909.
8
The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL.当 LDL-C 低于 104mg/dL 时,脂蛋白(a)与冠状动脉粥样硬化病变的相关性强于 LDL-C。
BMC Cardiovasc Disord. 2021 Jan 19;21(1):41. doi: 10.1186/s12872-021-01861-6.
9
Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Low-density Lipoprotein Cholesterol Levels in Older High-risk Adults.老年高危成年人中根据低密度脂蛋白胆固醇水平划分的脂蛋白(a)水平与心血管疾病、死亡风险及医疗费用的关系
Clin Cardiol. 2016 Jul;39(7):413-20. doi: 10.1002/clc.22546. Epub 2016 May 13.
10
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium.个体常规心血管危险因素和血管疾病风险的进展:PROG-IMT 联盟的见解。
Eur J Prev Cardiol. 2020 Feb;27(3):234-243. doi: 10.1177/2047487319877078. Epub 2019 Oct 16.

本文引用的文献

1
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.脂蛋白(a)与基线有或无动脉粥样硬化性心血管疾病患者的主要不良心血管事件。
J Am Coll Cardiol. 2024 Mar 5;83(9):873-886. doi: 10.1016/j.jacc.2023.12.031.
2
Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis.脂蛋白(a)升高个体中阿司匹林与心血管风险:动脉粥样硬化多族裔研究
J Am Heart Assoc. 2024 Feb 6;13(3):e033562. doi: 10.1161/JAHA.123.033562. Epub 2024 Jan 31.
3
Serum lipoprotein(a) and reclassification of coronary heart disease risk; application of prediction in a cross-sectional analysis of an ongoing Iranian cohort.
血清脂蛋白(a)与冠心病风险的再分类;在一项正在进行的伊朗队列的横断面分析中的预测应用。
BMC Public Health. 2023 Dec 2;23(1):2402. doi: 10.1186/s12889-023-17332-w.
4
Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)-A review of the evidence.对于脂蛋白升高的患者,阿司匹林治疗在一级预防中降低动脉粥样硬化性心血管疾病风险是否有益——证据综述
Am J Prev Cardiol. 2023 Sep 1;15:100579. doi: 10.1016/j.ajpc.2023.100579. eCollection 2023 Sep.
5
Association of statin use and increase in lipoprotein(a): a real-world database research.他汀类药物的使用与脂蛋白(a)的增加之间的关联:一项真实世界数据库研究。
Eur J Med Res. 2023 Jul 1;28(1):212. doi: 10.1186/s40001-023-01155-x.
6
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.2022 年欧洲动脉粥样硬化学会脂蛋白(a)共识声明的常见问题及解答。
Atherosclerosis. 2023 Jun;374:107-120. doi: 10.1016/j.atherosclerosis.2023.04.012. Epub 2023 Apr 28.
7
Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis.不同类型和剂量的前蛋白转化酶枯草溶菌素/克那霉 9 抑制剂对脂蛋白(a)水平的影响:网络荟萃分析。
J Cardiovasc Pharmacol. 2023 Jun 1;81(6):445-453. doi: 10.1097/FJC.0000000000001419.
8
Assessment of Cardiovascular Risk in Women: Progress so Far and Progress to Come.女性心血管风险评估:迄今的进展与未来的进展
Int J Womens Health. 2023 Feb 10;15:191-212. doi: 10.2147/IJWH.S364012. eCollection 2023.
9
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option.脂蛋白(a):心血管疾病、主动脉瓣狭窄和新的治疗选择。
Int J Mol Sci. 2022 Dec 22;24(1):170. doi: 10.3390/ijms24010170.
10
Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies.脂蛋白(a):作为心血管疾病因果风险因素的证据及新兴疗法
J Clin Med. 2022 Oct 13;11(20):6040. doi: 10.3390/jcm11206040.